Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Molecular targets on blood vessels for cancer therapies in clinical trials.

Sato M, Arap W, Pasqualini R.

Oncology (Williston Park). 2007 Oct;21(11):1346-52; discussion 1354-5, 1367, 1370 passim. Review.

2.

Anticancer strategies involving the vasculature.

Heath VL, Bicknell R.

Nat Rev Clin Oncol. 2009 Jul;6(7):395-404. doi: 10.1038/nrclinonc.2009.52. Epub 2009 May 7. Review.

PMID:
19424102
3.

Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.

Jain RK.

Semin Oncol. 2002 Dec;29(6 Suppl 16):3-9. Review.

PMID:
12516032
4.

Antiangiogenic agents in cancer therapy.

Lenz HJ.

Oncology (Williston Park). 2005 Apr;19(4 Suppl 3):17-25. Review.

5.

Novel therapeutic approaches for targeting tumor angiogenesis.

Linkous AG, Yazlovitskaya EM.

Anticancer Res. 2012 Jan;32(1):1-12. Review.

PMID:
22213282
6.

Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.

Grothey A, Ellis LM.

Cancer J. 2008 May-Jun;14(3):170-7. doi: 10.1097/PPO.0b013e318178d9de. Review.

PMID:
18536556
7.

Angiogenesis in cancer: molecular mechanisms, clinical impact.

Eichhorn ME, Kleespies A, Angele MK, Jauch KW, Bruns CJ.

Langenbecks Arch Surg. 2007 May;392(3):371-9. Epub 2007 Feb 16. Review.

PMID:
17458577
8.

New targeted probes for radioimaging of angiogenesis.

Stollman TH, Ruers TJ, Oyen WJ, Boerman OC.

Methods. 2009 Jun;48(2):188-92. doi: 10.1016/j.ymeth.2009.03.006. Epub 2009 Mar 24. Review.

PMID:
19318127
9.

Antiangiogenic cancer therapy.

Cao Y.

Semin Cancer Biol. 2004 Apr;14(2):139-45. Review.

PMID:
15018898
10.

Antiangiogenesis: current clinical data and future perspectives.

Drevs J, Laus C, Medinger M, Schmidt-Gersbach C, Unger C.

Onkologie. 2002 Dec;25(6):520-7. Review.

PMID:
12566896
11.

[Angiogenesis and antiangiogenic cancer therapy].

Pour L, Hájek R, Buchler T, Maisnar V, Smolej L.

Vnitr Lek. 2004 Dec;50(12):930-8. Review. Czech.

PMID:
15717808
12.

The therapeutic potential of novel antiangiogenic therapies.

Scappaticci FA.

Expert Opin Investig Drugs. 2003 Jun;12(6):923-32. Review.

PMID:
12783597
13.

Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.

Gacche RN, Meshram RJ.

Prog Biophys Mol Biol. 2013 Nov;113(2):333-54. doi: 10.1016/j.pbiomolbio.2013.10.001. Epub 2013 Oct 15. Review.

PMID:
24139944
14.

Vascular targeting therapy: potential benefit depends on tumor and host related effects.

Horsman MR, Bohn AB, Busk M.

Exp Oncol. 2010 Sep;32(3):143-8. Review.

PMID:
21403608
15.

The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer.

Los M, Voest EE.

Semin Oncol. 2001 Feb;28(1):93-105. Review.

PMID:
11254869
16.

[Rationale of antiangiogenic therapy].

Tímár J, Paku S, Tóvári J, Döme B.

Magy Onkol. 2006;50(2):141-51. Epub 2006 Aug 4. Review. Hungarian.

17.

Antiangiogenic therapy for cancer: current and emerging concepts.

Jain RK.

Oncology (Williston Park). 2005 Apr;19(4 Suppl 3):7-16. Review.

18.

Current development status of small-molecule vascular disrupting agents.

Chaplin DJ, Horsman MR, Siemann DW.

Curr Opin Investig Drugs. 2006 Jun;7(6):522-8. Review.

PMID:
16784022
19.

AVE8062: a new combretastatin derivative vascular disrupting agent.

Delmonte A, Sessa C.

Expert Opin Investig Drugs. 2009 Oct;18(10):1541-8. doi: 10.1517/13543780903213697. Review.

PMID:
19758109
20.

Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.

Rüegg C, Dormond O, Mariotti A.

Biochim Biophys Acta. 2004 Mar 4;1654(1):51-67. Review.

PMID:
14984767
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk